Annexin Pharmaceuticals AB (publ) Stock Nasdaq Stockholm
Equities
Biotechnology & Medical Research
Sales 2024 * | - | Sales 2025 * | 39.6M 3.62M | Capitalization | 103M 9.41M |
---|---|---|---|---|---|
Net income 2024 * | -52M -4.75M | Net income 2025 * | -16M -1.46M | EV / Sales 2024 * | - |
Net cash position 2024 * | 18.4M 1.68M | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.6 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 21.9% |
Managers | Title | Age | Since |
---|---|---|---|
Anna Frostegård
FOU | Founder | 51 | 13-12-31 |
Chief Executive Officer | 63 | 17-12-31 | |
Director of Finance/CFO | 53 | 23-04-10 |
Members of the board | Title | Age | Since |
---|---|---|---|
Uli Alf Hacksell
CHM | Chairman | 74 | 20-12-31 |
Mårten Österlund
BRD | Director/Board Member | 67 | 20-12-31 |
Chief Executive Officer | 63 | 17-12-31 |
1st Jan change | Capi. | |
---|---|---|
-2.31% | 103B | |
+0.56% | 95.71B | |
+1.69% | 22.02B | |
-17.37% | 20.9B | |
-9.30% | 17.85B | |
-41.01% | 16.21B | |
-14.85% | 15.52B | |
+3.21% | 13.86B | |
+33.54% | 12.04B |